Literature DB >> 23746185

High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6.

Greyson P Twist1, Roger Gaedigk, J Steven Leeder, Andrea Gaedigk.   

Abstract

High-resolution melt (HRM) analysis using 'release-on-demand' dyes, such as EvaGreen(®) has the potential to resolve complex genotypes in situations where genotype interpretation is complicated by the presence of pseudogenes or allelic variants in close proximity to the locus of interest. We explored the utility of HRM to genotype a SNP (785A>G, K262R, rs2279343) that is located within exon 5 of the CYP2B6 gene, which contributes to the metabolism of a number of clinically used drugs. Testing of 785A>G is challenging, but crucial for accurate genotype determination. This SNP is part of multiple known CYP2B6 haplotypes and located in a region that is identical to CYP2B7, a nonfunctional pseudogene. Because small CYP2B6-specific PCR amplicons bracketing 785A>G cannot be generated, we simultaneously amplified both genes. A panel of 235 liver tissue DNAs and five Coriell samples were assessed. Eight CYP2B6/CYP2B7 diplotype combinations were found and a novel variant 769G>A (D257N) was discovered. The frequency of 785G corresponded to those reported for Caucasians and African-Americans. Assay performance was confirmed by CYP2B6 and/or CYP2B7 sequence analysis in a subset of samples, using a preamplified CYP2B6-specific long-range-PCR amplicon as HRM template. Inclusion rather than exclusion of a homologous pseudogene allowed us to devise a sensitive, reliable and affordable assay to test this CYP2B6 SNP. This assay design may be utilized to overcome the challenges and limitations of other methods. Owing to the flexibility of HRM, this assay design can easily be adapted to other gene loci of interest.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23746185      PMCID: PMC3866959          DOI: 10.2217/pgs.13.66

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  41 in total

1.  Comparison of a high-resolution melting assay to next-generation sequencing for analysis of HIV diversity.

Authors:  Matthew M Cousins; San-San Ou; Maria J Wawer; Supriya Munshaw; David Swan; Craig A Magaret; Caroline E Mullis; David Serwadda; Stephen F Porcella; Ronald H Gray; Thomas C Quinn; Deborah Donnell; Susan H Eshleman; Andrew D Redd
Journal:  J Clin Microbiol       Date:  2012-07-11       Impact factor: 5.948

2.  Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms.

Authors:  Agnès Tran; François Bournerias; Christine Le Beller; Olivier Mir; Elisabeth Rey; Gérard Pons; Michel Delahousse; Jean-Marc Tréluyer
Journal:  Br J Clin Pharmacol       Date:  2007-09-13       Impact factor: 4.335

Review 3.  High-resolution melting analysis (HRMA): more than just sequence variant screening.

Authors:  Rolf H A M Vossen; Emmelien Aten; Anja Roos; Johan T den Dunnen
Journal:  Hum Mutat       Date:  2009-06       Impact factor: 4.878

4.  High-resolution melting curve analysis to establish CYP2C19∗2 single nucleotide polymorphism: Comparison with hydrolysis SNP analysis.

Authors:  Manna Temesvári; József Paulik; László Kóbori; Katalin Monostory
Journal:  Mol Cell Probes       Date:  2011-02-15       Impact factor: 2.365

5.  Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.

Authors:  Jing Li; Vincent Menard; Rebekah L Benish; Richard J Jurevic; Chantal Guillemette; Mark Stoneking; Peter A Zimmerman; Rajeev K Mehlotra
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

6.  MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms.

Authors:  Julia K Blievernicht; Elke Schaeffeler; Kathrin Klein; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  Clin Chem       Date:  2006-11-02       Impact factor: 8.327

7.  Rapid discrimination of MHC class I and killer cell lectin-like receptor allele variants by high-resolution melt analysis.

Authors:  Alyssa Lundgren; Sharon Kim; Michael D Stadnisky; Michael G Brown
Journal:  Immunogenetics       Date:  2012-07-01       Impact factor: 2.846

8.  Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.

Authors:  Leah M Hesse; Ping He; Soundararajan Krishnaswamy; Qin Hao; Kirk Hogan; Lisa L von Moltke; David J Greenblatt; Michael H Court
Journal:  Pharmacogenetics       Date:  2004-04

9.  Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.

Authors:  Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Journal:  Pharmacogenet Genomics       Date:  2008-06       Impact factor: 2.089

10.  Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.

Authors:  Zeruesenay Desta; Tanja Saussele; Bryan Ward; Julia Blievernicht; Lang Li; Kathrin Klein; David A Flockhart; Ulrich M Zanger
Journal:  Pharmacogenomics       Date:  2007-06       Impact factor: 2.533

View more
  5 in total

Review 1.  The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.

Authors:  N A Helsby; M Yong; M van Kan; J R de Zoysa; K E Burns
Journal:  Br J Clin Pharmacol       Date:  2019-07-22       Impact factor: 4.335

2.  Glucose-6-phosphate dehydrogenase mutations in malaria endemic area of Thailand by multiplexed high-resolution melting curve analysis.

Authors:  Usa Boonyuen; Duantida Songdej; Sasipa Tanyaratsrisakul; Suparat Phuanukoonnon; Kamonwan Chamchoy; Aun Praoparotai; Phonchanan Pakparnich; Sirapapha Sudsumrit; Thomas Edwards; Christopher T Williams; Rachel L Byrne; Emily R Adams; Mallika Imwong
Journal:  Malar J       Date:  2021-04-20       Impact factor: 2.979

3.  Sexing chickens (Gallus gallus domesticus) with high-resolution melting analysis using feather crude DNA.

Authors:  A D England; S K Kheravii; S Musigwa; A Kumar; A Daneshmand; N K Sharma; K Gharib-Naseri; S B Wu
Journal:  Poult Sci       Date:  2020-12-13       Impact factor: 3.352

4.  Variants in the CYP2B6 3'UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs.

Authors:  Kimberly S Burgess; Joseph Ipe; Marelize Swart; Ingrid F Metzger; Jessica Lu; Brandon T Gufford; Nancy Thong; Zeruesenay Desta; Roger Gaedigk; Robin E Pearce; Andrea Gaedigk; Yunlong Liu; Todd C Skaar
Journal:  Clin Pharmacol Ther       Date:  2017-10-25       Impact factor: 6.875

5.  Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation.

Authors:  Robin E Pearce; Roger Gaedigk; Greyson P Twist; Hongying Dai; Amanda K Riffel; J Steven Leeder; Andrea Gaedigk
Journal:  Drug Metab Dispos       Date:  2015-11-25       Impact factor: 3.922

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.